A Phase 3 interventional study of Lopinavir/Ritonavir and Nelfinavir mesylate in HIV Infections, sponsored by Abbott. Completed at 83 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2009-02-20.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing nelfinavir in HIV Infections — none open to participants now, none under way, none of them phase 3. Nelfinavir · HIV Infections.
Among the 45 studies testing nelfinavir in HIV Infections, this one is the 5th largest by enrollment of the 37 interventional ones that give a count, is one of 5 that started in 1999, is one of 9 in phase 3, and was the 1st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 45 studies testing nelfinavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →
Nelfinavir: first FDA approval 1997 (VIRACEPT), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 5 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 660 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 103 across the 37 interventional studies. Of the 39 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 45 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
27 studies in HIV Infections by Abbott: none open now, none under way, none of them phase 3. Of 26 finished, 0 (0%) have results posted.
Among the 27 studies in HIV Infections by Abbott, this one has the largest enrollment of the 18 interventional ones that give a count, is the only one that started in 1999, is one of 6 in phase 3, and was the 1st registered.
Abbott’s HIV Infections studies by the year they started, since 1992.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing nelfinavir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 27 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see how safe a new protease inhibitor (PI) is and how well it fights HIV infection. A PI is a drug that stops HIV from using healthy cells to make more virus. This study will compare the new PI combination of ABT-378 plus ritonavir (RTV) with another PI, nelfinavir (NFV).
Earlier studies suggest ABT-378/RTV will be just as good as and perhaps better than NFV at fighting HIV infection.
Based on the accumulated studies to date, it is expected that ABT-378/ritonavir will provide efficacy that is at least as good as (or superior to) nelfinavir when used in combination with reverse transcriptase inhibitors.
Patients are equally randomized to one of two treatment arms. In one arm, approximately 330 patients receive ABT-378/ritonavir plus nelfinavir placebo. In the other arm, approximately 330 patients receive nelfinavir plus ABT-378/ritonavir placebo. In both arms, these protease inhibitors are blinded to the investigator, patient, and sponsor. Both arms receive open-label stavudine and lamivudine. Vital sign measurements, physical examinations, ECGs, routine clinical laboratory evaluations, and determinations of antiviral and immunologic activity are performed at intervals throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
You may be eligible for this trial if you:
Exclusion Criteria
You will not be eligible for this trial if you:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nelfinavir · Lamivudine · Stavudine